iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

iRadimed Corporation (NASDAQ:IRMD) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $87.3333.

A number of research firms have commented on IRMD. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday. Roth Capital set a $90.00 target price on iRadimed in a research report on Friday, October 31st. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Finally, Lake Street Capital reissued a “buy” rating and set a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd.

iRadimed Stock Performance

Shares of IRMD stock opened at $97.04 on Friday. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 58.81 and a beta of 1.06. iRadimed has a one year low of $47.48 and a one year high of $98.44. The company’s 50-day moving average is $88.24 and its 200 day moving average is $73.89.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, research analysts predict that iRadimed will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently declared a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be paid a $0.50 dividend. The ex-dividend date is Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is 41.21%.

Insider Transactions at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $96.73, for a total value of $483,650.00. Following the transaction, the chief executive officer owned 2,287,500 shares in the company, valued at $221,269,875. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. The trade was a 67.08% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 65,000 shares of company stock worth $5,548,150. 36.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IRMD. CWM LLC grew its position in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the period. Quarry LP purchased a new stake in iRadimed in the third quarter worth about $40,000. Tower Research Capital LLC TRC raised its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of iRadimed during the 3rd quarter valued at about $47,000. Finally, Spire Wealth Management purchased a new position in shares of iRadimed during the 2nd quarter valued at about $60,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.